单克隆抗体:目前的进展和未来的潜力,用于治疗亚托匹性皮炎
Pravin Kumar1, Mahendra Singh Ashawat1, Ajay Kumar1
1Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, H.P, 176031, India.
Current pharmaceutical biotechnology
|June 26, 2024
概括
向单克隆抗体为管理中度至严重的亚托皮性皮肤炎 (AD) 提供了新的希望. 这些先进的疗法正在改善患者的治疗结果,并代表了AD治疗的未来.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 无氧性皮肤炎 (AD) 是一种慢性炎症性皮肤疾病,其特征是剧烈的.
- 目前的局部皮质类固醇疗法往往不足以适度至严重的AD病例.
- 针对性免疫疗法的发展已经显著提升了AD治疗范式.
研究的目的:
- 审查人类单克隆抗体对中度至严重的亚托皮性皮肤炎的免疫学目标和临床疗效.
- 评估基于抗体的新型疗法在治疗AD方面的潜力.
主要方法:
- 使用PubMed和clinicaltrials.gov.gov等数据库进行了全面的文献搜索.
- 分析了相关的临床试验数据和对AD单克隆抗体的治疗信息.
- 该审查重点关注已批准和正在研究的向单克隆抗体.
主要成果:
- 已经确定了AD中单克隆抗体发展的几个免疫标.
- 针对特定免疫路径的单克隆抗体显示出有效AD管理的希望.
- 临床试验正在评估这些向治疗的安全性和有效性.
结论:
- 向单克隆抗体在治疗中度至严重的亚托皮性皮肤炎方面取得了重大进展.
- 对免疫路径和生物标志物的进一步研究将完善未来的AD治疗方法.
- 这些疗法有望改善阿尔茨海默病患者的治疗结果和疾病控制.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
Hybridoma Technology
14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Cross-reactivity
31.0K
Overview
31.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130


